Not-for-the-Market (NHSL1) Gene: A Potential Drug Target and Biomarker for Various Diseases

Target Name: NHSL1

NCBI ID: G57224

NHSL1

Not-for-the-Market (NHSL1) Gene: A Potential Drug Target and Biomarker for Various Diseases

The Not-for-the-Market (NHSL1) gene is a highly conserved non-coding RNA molecule that is expressed in various tissues of the human body. It is a key regulator of gene expression and has been implicated in the development and progression of various diseases, including cancer. The NHSL1 gene has also been identified as a potential drug target and biomarker for the treatment of various diseases.

The NHSL1 gene was first identified in the late 1990s as a potential gene that was involved in the regulation of cell growth and differentiation. Subsequent studies have shown that the NHSL1 gene plays a critical role in the regulation of various cellular processes, including cell cycle progression, apoptosis (programmed cell death), angiogenesis (the formation of new blood vessels), and tissue repair.

One of the key functions of the NHSL1 gene is its role in the regulation of cell cycle progression. The cell cycle is the process by which a cell grows, replicates its DNA, and divides. The NHSL1 gene is involved in the regulation of the G1 phase of the cell cycle, which is the stage at which the cell prepares for cell division.

Studies have shown that the NHSL1 gene plays a critical role in the regulation of the G1 phase of the cell cycle. It is expressed in the S phase of the cell cycle and is required for the accumulation of specific RNA molecules at the nuclear envelope, which are necessary for the initiation of the G1 phase. Additionally, the NHSL1 gene is involved in the regulation of the G2 phase of the cell cycle, which is the stage at which the cell prepares for cell division.

Another function of the NHSL1 gene is its role in the regulation of apoptosis. Apoptosis is a critical mechanism of cell death that is involved in the regulation of cellular processes such as growth, differentiation, and stress resistance. The NHSL1 gene is involved in the regulation of apoptosis by promoting the expression of genes that are involved in the formation of apoptosis-associated mitochondrial structures (AMSMs). These structures are composed of interconnected mitochondrial proteins that form a barrier around the mitochondria, preventing them from releasing harmful products during apoptosis.

The NHSL1 gene is also involved in the regulation of angiogenesis, the formation of new blood vessels. Angiogenesis is the process by which new blood vessels are formed in the body to supply oxygen and nutrients to tissues. The NHSL1 gene is involved in the regulation of angiogenesis by promoting the expression of genes that are involved in the formation of blood vessels.

In addition to its role in the regulation of cell cycle progression, apoptosis, and angiogenesis, the NHSL1 gene is also involved in the regulation of tissue repair. Tissue repair is a critical process that occurs in response to tissue damage or injury. The NHSL1 gene is involved in the regulation of tissue repair by promoting the expression of genes that are involved in the formation of new tissue repair templates.

Due to its involvement in the regulation of various cellular processes, the NHSL1 gene has been identified as a potential drug target and biomarker for the treatment of various diseases. For example, studies have shown that inhibiting the expression of the NHSL1 gene has been shown to be effective in treating cancer, including breast cancer. This is because the NHSL1 gene is involved in the regulation of cell cycle progression, which is a critical factor in the development and progression of cancer.

In addition to its potential as a drug target, the NHSL1 gene has also been identified as a potential biomarker for the diagnosis and prognosis of various diseases. For example, studies have shown that the expression of the NHSL1 gene is increased in the blood and lymphatic tissues of patients with breast cancer, and that its expression is associated with poor prognosis. Additionally, the NHS

Protein Name: NHS Like 1

The "NHSL1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NHSL1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets